$Kazia Therapeutics (KZIA.US)$ kazia therapeutics宣布在第15届卵巢癌研讨会上展示EVT801临床数据 悉尼,2024年9月23日/PRNewswire/--纳斯达克: kazia therapeutics有限公司(NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the presentation of data highlighting promising clinical activity of EVT801 in high grade serous (HGS) Ovarian Cancer at the 15thBiennial Ovarian Cancer Research Symposium, co-presented by American ...
Kazia Therapeutics股票讨论
kazia therapeutics宣布在美国肿瘤放射治疗学会66届年会上展示了有前景的I期数据,评估了在患有固体肿瘤脑转移或蛛网膜肿瘤的患者中同时使用帕克萨利西布和放射治疗,这些患者携带PI0.3万通路突变。
kazia therapeutics宣布在第66届美国放射肿瘤学会年会上展示了有前途的I期数据,评估了同时使用Paxalisib和放射治疗治疗携带PI0.3万通路突变的实体肿瘤脑转移或脑膜转移患者
使用45mg的paxalisib和放疗治疗,显示67%的部分缓解(PR)
超过三分之二的患者在最大耐受剂量(MTD)下实现颅内...
kazia therapeutics宣布在第15届卵巢癌研讨会上展示EVT801临床数据
悉尼,2024年9月23日/PRNewswire/--纳斯达克: kazia therapeutics有限公司(NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the presentation of data highlighting promising clinical activity of EVT801 in high grade serous (HGS) Ovarian Cancer at the 15thBiennial Ovarian Cancer Research Symposium, co-presented by American ...
暂无评论